Advertisement

Lymphoma Risk and Screening in IBD

  • Chip Alex Bowman
  • Garrett LawlorEmail author
Chapter

Abstract

Our understanding of the risk of lymphoma in inflammatory bowel disease (IBD) is confounded by conflicting data, the impact of immunosuppressive medications on that risk, and the introduction of newer agents in the management of IBD. As we alter how we strategize, stratify, and combine therapies, this risk will also alter. Recent data is reassuring in downplaying the risk of lymphoma associated with anti-TNF therapies specifically and brings to the forefront legitimate concerns of thiopurine (6-MP, azathioprine) use, especially in young men. This chapter will discuss the impact of IBD and IBD therapies on overall lymphoma risk. We will also discuss the role of Epstein-Barr virus (EBV) in the development of lymphoma and our evolving understanding of the risk of hepatosplenic T-cell lymphoma (HSTCL) with IBD therapies.

Keywords

Lymphoma IBD Inflammatory bowel disease Crohn’s disease Ulcerative colitis Thiopurines Anti-TNF EBV HSTCL Vedolizumab Tofacitinib 

References

  1. 1.
    Eichenauer DA, Engert A, André M, et al. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii70–i5.CrossRefGoogle Scholar
  2. 2.
    Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–52.CrossRefGoogle Scholar
  3. 3.
    Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.CrossRefGoogle Scholar
  4. 4.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefGoogle Scholar
  5. 5.
    Horesh N, Horowitz NA. Does gender matter in non-Hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014;5:e0038.CrossRefGoogle Scholar
  6. 6.
    Cancer stat facts: non-Hodgkin lymphoma. seer.cancer.gov. Accessed 9 Oct 2018.
  7. 7.
    Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.CrossRefGoogle Scholar
  8. 8.
    Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L. Cancer and inflammatory bowel disease in the elderly. Dig Liver Dis. 2016;48:1105–11.CrossRefGoogle Scholar
  9. 9.
    Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013;19:1384–9.CrossRefGoogle Scholar
  10. 10.
    Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265–73.e1.CrossRefGoogle Scholar
  11. 11.
    Garg SK, Velayos FS, Kisiel JB. Intestinal and nonintestinal cancer risks for patients with Crohn’s disease. Gastroenterol Clin. 2017;46:515–29.CrossRefGoogle Scholar
  12. 12.
    Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299–307.CrossRefGoogle Scholar
  13. 13.
    Farrell R, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514–9.CrossRefGoogle Scholar
  14. 14.
    Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080–7.CrossRefGoogle Scholar
  15. 15.
    Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95:2308.CrossRefGoogle Scholar
  16. 16.
    Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer. 1992;69:1119–23.CrossRefGoogle Scholar
  17. 17.
    Garg SK, Loftus EV. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same? Curr Opin Gastroenterol. 2016;32:274–81.CrossRefGoogle Scholar
  18. 18.
    van den Heuvel TR, Wintjens DS, Jeuring SF, et al. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer. 2016;139:1270–80.CrossRefGoogle Scholar
  19. 19.
    Vos A, Bakkal N, Minnee R, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis. 2011;17:1837–45.CrossRefGoogle Scholar
  20. 20.
    Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol. 2005;56:169–78.CrossRefGoogle Scholar
  21. 21.
    Wheat CL, Clark-Snustad K, Devine B, Grembowski D, Thornton TA, Ko CW. Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: an updated systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:1632439.CrossRefGoogle Scholar
  22. 22.
    Shrestha MP, Ruel J, Taleban S. Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30:273.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306–21.CrossRefGoogle Scholar
  24. 24.
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018–24.CrossRefGoogle Scholar
  25. 25.
    Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. 2015.CrossRefGoogle Scholar
  26. 26.
    Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:621–31.CrossRefGoogle Scholar
  27. 27.
    McGovern DP, Travis SP. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol. 2003;15:219–23.CrossRefGoogle Scholar
  28. 28.
    Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146.CrossRefGoogle Scholar
  29. 29.
    Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.CrossRefGoogle Scholar
  30. 30.
    Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014;20:926–35.CrossRefGoogle Scholar
  31. 31.
    Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefGoogle Scholar
  32. 32.
    Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007–15.e3.CrossRefGoogle Scholar
  33. 33.
    Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.e4.CrossRefGoogle Scholar
  34. 34.
    Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729–35.CrossRefGoogle Scholar
  35. 35.
    D’Haens G, Reinisch W, Panaccione R, et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn’s disease with up to 6 years of follow-up in the pyramid registry. Am J Gastroenterol. 2018;1:872–82.Google Scholar
  36. 36.
    Andersen NN, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406–13.CrossRefGoogle Scholar
  37. 37.
    Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–51.CrossRefGoogle Scholar
  38. 38.
    Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447–58.CrossRefGoogle Scholar
  39. 39.
    Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847–53.CrossRefGoogle Scholar
  40. 40.
    Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1464–78.e5.CrossRefGoogle Scholar
  41. 41.
    Chen Y, Friedman M, Liu G, Deodhar A, Chu C-Q. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78–88.CrossRefGoogle Scholar
  42. 42.
    Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: safety. Am J Gastroenterol. 2011;106:1594.CrossRefGoogle Scholar
  43. 43.
    Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.CrossRefGoogle Scholar
  44. 44.
    Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut. 2006;55:228–33.CrossRefGoogle Scholar
  45. 45.
    Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn’s disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2010;17:758–66.CrossRefGoogle Scholar
  46. 46.
    Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–8.CrossRefGoogle Scholar
  47. 47.
    Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–14.e3.CrossRefGoogle Scholar
  48. 48.
    Miehsler W, Novacek G, Wenzl H, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohn’s Colitis. 2010;4:221–56.CrossRefGoogle Scholar
  49. 49.
    Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212–7.CrossRefGoogle Scholar
  50. 50.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ registry. Am J Gastroenterol. 2014;109:212.CrossRefGoogle Scholar
  51. 51.
    Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:514–21.e4.CrossRefGoogle Scholar
  52. 52.
    Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835.CrossRefGoogle Scholar
  53. 53.
    Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.CrossRefGoogle Scholar
  54. 54.
    Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn’s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis. 2004;10:85–90.CrossRefGoogle Scholar
  55. 55.
    Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165–71.CrossRefGoogle Scholar
  56. 56.
    Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72–7.CrossRefGoogle Scholar
  57. 57.
    Serrate C, Silva-Moreno M, Dartigues P, et al. Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn’s disease. Inflamm Bowel Dis. 2009;15:1449–51.CrossRefGoogle Scholar
  58. 58.
    Virdis F, Tacci S, Messina F, Varcada M. Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn’s disease. World J Gastrointest Surg. 2013;5:306–8.CrossRefGoogle Scholar
  59. 59.
    Münz C, Moormann A. Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol. 2008;18:381–7. Elsevier.CrossRefGoogle Scholar
  60. 60.
    Gordon J, Ramaswami A, Beuttler M, et al. EBV status and thiopurine use in pediatric IBD. J Pediatr Gastroenterol Nutr. 2016;62:711–4.CrossRefGoogle Scholar
  61. 61.
    Biank VF, Sheth MK, Talano J, et al. Association of Crohn’s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr. 2011;159:808–12.CrossRefGoogle Scholar
  62. 62.
    van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–9.CrossRefGoogle Scholar
  63. 63.
    Weinstock D, Ambrossi G, Brennan C, Kiehn T, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539.CrossRefGoogle Scholar
  64. 64.
    Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn’s Colitis. 2010;4:511–22.CrossRefGoogle Scholar
  65. 65.
    Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.e1.CrossRefGoogle Scholar
  66. 66.
    Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639.CrossRefGoogle Scholar
  67. 67.
    Mekelburg S, Schneider Y, Pizzi M, Chadburn A, Mathew S. The risk of hepatosplenic T-cell lymphoma (HSTCL) in women with inflammatory bowel disease (IBD) on thiopurines. J Inflam Bowel Dis Disord. 2016;1:110; 3:3Google Scholar
  68. 68.
    FDA. Hepatosplenic T-cell lymphoma. FDA adverse events reporting system (FAERS) 2018.Google Scholar
  69. 69.
    Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin. 2014;43:525–41.CrossRefGoogle Scholar
  70. 70.
    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99.CrossRefGoogle Scholar
  71. 71.
    Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024–30.CrossRefGoogle Scholar
  72. 72.
    Dulai PS, Siegel CA, Colombel J-F, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63:1843–53.CrossRefGoogle Scholar
  73. 73.
    Aardoom MA, Joosse ME, de Vries ACH, Levine A, de Ridder L. Malignancy and mortality in pediatric-onset inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2018;24:732–41.CrossRefGoogle Scholar
  74. 74.
    Bernheim O, Colombel J-F, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013;62:1523–8.CrossRefGoogle Scholar
  75. 75.
    Axelrad J, Bernheim O, Colombel J-F, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58–64.CrossRefGoogle Scholar
  76. 76.
    Beaugerie L, Carrat F, Colombel J-F, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416–23.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Columbia University Vagelos College of Physicians and SurgeonsNew YorkUSA
  2. 2.Columbia University Medical Center/NY-Presbyterian HospitalNew YorkUSA

Personalised recommendations